Global, Regional, and National Burden of Pharyngeal Cancer and Projections to 2050 in 185 Countries: A Population-Based Systematic Analysis of GLOBOCAN 2022.

IF 2.3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Wonwoo Jang, Seokjun Kim, Yejun Son, Soeun Kim, Sooji Lee, Hyeon Jin Kim, Hyesu Jo, Jaeyu Park, Kyeongmin Lee, Hayeon Lee, Masoud Rahmati, Selin Woo, Jiyoung Hwang, Jiseung Kang, Lee Smith, Dong Keon Yon
{"title":"Global, Regional, and National Burden of Pharyngeal Cancer and Projections to 2050 in 185 Countries: A Population-Based Systematic Analysis of GLOBOCAN 2022.","authors":"Wonwoo Jang, Seokjun Kim, Yejun Son, Soeun Kim, Sooji Lee, Hyeon Jin Kim, Hyesu Jo, Jaeyu Park, Kyeongmin Lee, Hayeon Lee, Masoud Rahmati, Selin Woo, Jiyoung Hwang, Jiseung Kang, Lee Smith, Dong Keon Yon","doi":"10.3346/jkms.2025.40.e177","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pharyngeal cancer has resulted in 3.23 million disability-adjusted life years as of 2019. Based on anatomical site, pharyngeal cancers are categorized into oropharyngeal cancers (OPCs), nasopharyngeal cancers (NPCs), and hypopharyngeal cancers (HPCs). The spatiotemporal distribution of each pharyngeal cancer is related to their respective risk factors.</p><p><strong>Methods: </strong>Using the latest updated GLOBOCAN 2022 and Cancer Incidence in Five Continents database, global, regional, and national age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of pharyngeal cancer by anatomical site, as well as longitudinal trends since 1998 and future projections to 2050 were investigated across 185 countries and territories. We employed joinpoint regression to assess the average annual percentage change to quantify trends in the ASIR of pharyngeal cancer. We additionally present the mortality-to-incidence ratio as an indicator of disease fatality.</p><p><strong>Results: </strong>In 2022, an estimated 313,091 people were diagnosed with pharyngeal cancer (ASIR, 3.3 per 100,000 person-years) and 166,689 people died from pharyngeal cancer worldwide (ASMR, 1.7 per 100,000 person-years). Regardless of an individual's age and anatomical site, pharyngeal cancer exhibits significantly higher incidence and mortality rates in old males, and the highest number of cases and deaths occur in individuals aged 45-59 years in both sexes. The highest ASIRs per 100,000 person-years were found in Western Europe (2.6) and Northern America (2.6) for OPC, South-Eastern Asia (4.7) for NPCs, South Central Asia (2.1) and Eastern Europe (1.5) for HPC. ASMR per 100,000 person-years were higher for OPC and HPC in Eastern Europe (OPC, 1.1; HPC, 1.0), South Central Asia (OPC, 0.9; HPC, 0.8), and for NPC in South-Eastern Asia (3.1), and Micronesia (2.1). In most countries, the incidence of OPC either increased or remained at a similar level, and NPC remained stable in most countries and HPC decreased or remained unchanged in both sexes. If the ASIR and ASMR of 2022 are maintained, in 2050, the projected number of cases will increase by 63.64% for OPC, 46.40% for NPC, and 64.23% for HPC.</p><p><strong>Conclusion: </strong>Pharyngeal cancer represents a significant burden on global public health, with its disease burden varying across different demographic variables. These variations were closely associated with risk factors such as tobacco and alcohol use, high-risk human papillomavirus, and Epstein-Barr virus infections. To effectively manage the current and future global burden, tailored interventions aligned with unique epidemiological profiles of pharyngeal cancer in diverse populations are required.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"40 30","pages":"e177"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12322593/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2025.40.e177","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pharyngeal cancer has resulted in 3.23 million disability-adjusted life years as of 2019. Based on anatomical site, pharyngeal cancers are categorized into oropharyngeal cancers (OPCs), nasopharyngeal cancers (NPCs), and hypopharyngeal cancers (HPCs). The spatiotemporal distribution of each pharyngeal cancer is related to their respective risk factors.

Methods: Using the latest updated GLOBOCAN 2022 and Cancer Incidence in Five Continents database, global, regional, and national age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of pharyngeal cancer by anatomical site, as well as longitudinal trends since 1998 and future projections to 2050 were investigated across 185 countries and territories. We employed joinpoint regression to assess the average annual percentage change to quantify trends in the ASIR of pharyngeal cancer. We additionally present the mortality-to-incidence ratio as an indicator of disease fatality.

Results: In 2022, an estimated 313,091 people were diagnosed with pharyngeal cancer (ASIR, 3.3 per 100,000 person-years) and 166,689 people died from pharyngeal cancer worldwide (ASMR, 1.7 per 100,000 person-years). Regardless of an individual's age and anatomical site, pharyngeal cancer exhibits significantly higher incidence and mortality rates in old males, and the highest number of cases and deaths occur in individuals aged 45-59 years in both sexes. The highest ASIRs per 100,000 person-years were found in Western Europe (2.6) and Northern America (2.6) for OPC, South-Eastern Asia (4.7) for NPCs, South Central Asia (2.1) and Eastern Europe (1.5) for HPC. ASMR per 100,000 person-years were higher for OPC and HPC in Eastern Europe (OPC, 1.1; HPC, 1.0), South Central Asia (OPC, 0.9; HPC, 0.8), and for NPC in South-Eastern Asia (3.1), and Micronesia (2.1). In most countries, the incidence of OPC either increased or remained at a similar level, and NPC remained stable in most countries and HPC decreased or remained unchanged in both sexes. If the ASIR and ASMR of 2022 are maintained, in 2050, the projected number of cases will increase by 63.64% for OPC, 46.40% for NPC, and 64.23% for HPC.

Conclusion: Pharyngeal cancer represents a significant burden on global public health, with its disease burden varying across different demographic variables. These variations were closely associated with risk factors such as tobacco and alcohol use, high-risk human papillomavirus, and Epstein-Barr virus infections. To effectively manage the current and future global burden, tailored interventions aligned with unique epidemiological profiles of pharyngeal cancer in diverse populations are required.

全球、地区和国家咽癌负担以及到2050年185个国家的预测:GLOBOCAN 2022基于人群的系统分析
背景:截至2019年,咽喉癌已导致323万残疾调整生命年。根据解剖部位,咽癌可分为口咽癌(OPCs)、鼻咽癌(npc)和下咽癌(HPCs)。每种咽喉癌的时空分布与其各自的危险因素有关。方法:使用最新更新的GLOBOCAN 2022和五大洲癌症发病率数据库,调查185个国家和地区按解剖部位划分的咽喉癌全球、区域和国家年龄标准化发病率(asir)和年龄标准化死亡率(ASMRs),以及1998年以来的纵向趋势和2050年的未来预测。我们采用联结点回归来评估咽癌ASIR的年平均百分比变化,以量化其趋势。我们还提出了死亡率与发病率之比作为疾病病死率的指标。结果:2022年,全球估计有313091人被诊断为咽癌(ASIR,每10万人年3.3人),166689人死于咽癌(ASMR,每10万人年1.7人)。无论个人的年龄和解剖部位如何,老年男性咽喉癌的发病率和死亡率都明显更高,45-59岁的男性和女性咽喉癌的病例和死亡人数最多。每10万人年最高的asir分布在西欧(2.6)和北美(2.6)的OPC,东南亚(4.7)的npc,中南亚(2.1)和东欧(1.5)的HPC。东欧的OPC和HPC患者每10万人年的ASMR更高(OPC, 1.1;HPC, 1.0),中南亚(OPC, 0.9;HPC, 0.8),东南亚(3.1)和密克罗尼西亚(2.1)的NPC。在大多数国家,OPC的发病率增加或保持在相似的水平,NPC在大多数国家保持稳定,HPC在两性中下降或保持不变。如果维持2022年的ASIR和ASMR,到2050年,预计OPC病例数将增加63.64%,NPC增加46.40%,HPC增加64.23%。结论:咽喉癌是全球公共卫生的重大负担,其疾病负担因不同的人口统计变量而异。这些变异与吸烟和饮酒、高危人乳头瘤病毒和eb病毒感染等风险因素密切相关。为了有效管理当前和未来的全球负担,需要根据不同人群中咽喉癌的独特流行病学概况进行量身定制的干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Korean Medical Science
Journal of Korean Medical Science 医学-医学:内科
CiteScore
7.80
自引率
8.90%
发文量
320
审稿时长
3-6 weeks
期刊介绍: The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信